微量和外显子的纸基预集中和分离

Executive Industry Relevance

Isolation of extracellular vesicles remains a bottleneck in biomarker discovery due to low yield and sample damage from conventional methods. The paper-based Exo-PAD enables chemical-free, fivefold enrichment of microvesicles and exosomes, improving recovery while preserving vesicle integrity. This supports early-stage target validation and assay development by providing a scalable, reproducible workflow for downstream omics and functional analysis.

Strategic Applications in Biopharma R&D

Early Discovery & Target Validation

• Scientific Value: Enables interrogation of therapeutic hypotheses through enriched vesicle cargo analysis.
• Operational Value: Reduces sample loss and damage compared to ultracentrifugation, increasing usable material for target de-risking.
• Predictive Value: Fivefold enrichment improves signal detection in low-abundance biomarkers, supporting portfolio triage decisions.

Screening & Assay Development

• Scientific Value: Produces standardized, concentrated vesicle preparations suitable for assay standardization.
• Operational Value: Eliminates need for centrifuges or chemicals, simplifying workflow and reducing operational complexity.
• Scalability: Paper-based design allows parallel processing and platform reuse across multiple sample types.

Translational & Preclinical Research

• Translational Continuity: Enriched vesicles maintain integrity for downstream functional assays and biomarker profiling.
• Disease-Relevant Systems: Compatible with biofluids like serum or plasma when used with carbonate buffer, supporting clinical relevance.
• Mechanistic De-risking: Reliable isolation enables consistent evaluation of vesicle-mediated mechanisms in preclinical models.

Pipeline & Workflow Integration

The Exo-PAD fits within the discovery continuum from hypothesis testing to lead identification, enabling reliable vesicle preparation for analytical and functional downstream applications.

• Discovery Biology: Supports functional target validation by providing intact vesicles for cargo analysis and pathway interrogation.
• Screening: Delivers reproducible, quantitative outputs essential for assay readiness and compound screening campaigns.
• Analytics: Enables fluorescence-based quantification and size distribution analysis for comparative condition evaluation.
• Translational Research: Facilitates continuity from discovery to preclinical validation through preserved vesicle structure and function.
• Enterprise Reuse: Simple fabrication and operation allow adoption as a reusable platform across teams and projects.

Operational & Enterprise Impact

• Scientific Value: Improves target validation confidence through higher recovery and intact vesicle isolation.
• Operational Value: Standardizes enrichment process, reduces reagent waste, and eliminates equipment dependency.
• Strategic Value: Enhances go/no-go decision quality by reducing false negatives in biomarker detection.
• Portfolio Impact: Enables risk-adjusted advancement through reliable, scalable vesicle preparation for diagnostic and therapeutic applications.

Implementation Considerations

• Requires expertise in wax patterning and ion concentration polarization principles for device fabrication.
• Needs access to laboratory oven, hot plate, cutter, and voltage source for operation.
• Demands standardization of sample volume, buffer composition, and processing time across users.
• Adaptation to viscous biofluids may require buffer optimization, such as carbonate serum/plasma compatibility.
• Practical limitation: Enrichment is layer-specific (layers 8–9), requiring precise puning for downstream analysis.

Biopharma FAQs